Lung Cancer

CRTC-MAML2 fusions are also present in mucoepidermoid carcinomas of the lung, cervix, thyroid, and oral cavity, as well as in clear cell sweat adenocarcinomas of the skin. Particularly in lung mucoepidermoid carcinoma, clinical sensitivity to gefitinib in the absence of EGFR mutations suggests a possible association with CRTC-MAML2 and offers a possibility for the treatment of other selected mucoepidermoid carcinomas.MAML2 gene breakthrough probes can be used for the adjuvant diagnosis of mucoepidermoid carcinoma.

Salivary gland tumors

Mucoepidermoid carcinoma is mainly distinguished from Warthin's tumor with squamous metaplasia, pleomorphic adenoma with squamous metaplasia, sebaceous glands or tumors with squamous metaplasia, squamous cell carcinoma, and poorly differentiated carcinoma. Approximately 50% of mucoepidermoid carcinomas have a characteristic t(11;19) translocation leading to the formation of the MAML2-CRTC1 (MECT1) fusion protein. In contrast, mucoepidermoid carcinomas with negative translocations are considered a distinct subtype of adenosquamous carcinomas.MAML2 gene breakage probes can be used for the adjunctive diagnosis of mucoepidermoid carcinomas.